Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
Subsequent treatments and outcomes in bacillus Calmette-Guerin–unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world data analysis. This is an ...
Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...
Analysis of the results of intravesical perfusion therapy combined with immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy (PDT) after TURBT for NMIBC. This is an ...
LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Bladder cancer imaging and diagnosis have evolved significantly with the integration of advanced magnetic resonance imaging (MRI) techniques and artificial intelligence (AI)-driven analytical methods.
A validated risk score based on 12 aging-related genes (ARGs) in bladder cancer showed "considerable potential" as an independent predictor of clinical prognosis in patients with newly diagnosed ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results